DTx Digital Therapeutics
DTx, or Digital Therapeutics, refers to digital products that provide evidence-based therapeutic interventions for the treatment, management, and prevention of diseases and conditions. It is expected to be a new modality in a wide range of medical and healthcare fields. However, since the process of prescribing DTx differs from that of conventional medical pharmaceuticals, there is a need to consider and establish new mechanisms to deliver DTx to patients safely and efficiently. In addition, healthcare institutions and DTx providers typically have individual contracts on a one-to-one basis for prescription registration and billing. However, if the contract processes and payment specifications vary among providers, it may become burdensome for healthcare institutions to handle administrative procedures. Therefore,
The launch of the Platform is scheduled for 2025. This Platform aims to standardize and centralize the coordination of necessary information between patients, healthcare institutions, and DTx providers. It consolidates various functions such as contracts, billing, and prescription registration between healthcare institutions and DTx providers, aiming to reduce the burden on both parties and establish a safer and more efficient prescription and distribution system.
About
About
In the medical and healthcare industry,
About
As a member of
Forward-Looking Statements
This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Contact:
Web: https://www.shionogi.com
(C) 2024 Electronic News Publishing, source